ÈçºÎ·¢ÏÖ¡°RAǰ״̬¡±

2025-06-18 10:00:00

ʲôÊÇRA

Àà·çʪ¹Ø½ÚÑ×£¨RA£©ÊÇÒ»ÖÖÒÔÇÖÊ´ÐԹؽÚÑ×ΪÖ÷ÒªÁÙ´²±íÏÖµÄ×ÔÉíÃâÒß²¡£¬¿Éµ¼Ö¹ؽڻûÐκ͹¦ÄÜɥʧ£¬ÉõÖÁ²Ð¼²£¬Í¬Ê±²¢·¢ÐÄѪ¹ÜϵͳºÍºôÎüϵͳµÈ¶àϵͳÆ÷¹Ù¼²²¡£¬¸ø»¼Õ߸öÈ˺ͼÒÍ¥£¬ÒÔ¼°Éç»á¾ù´øÀ´Á˾޴óµÄ½¡¿µ¸ºµ£ºÍ¾­¼Ã¸ºµ£¡£  ¡¶ÖйúÀà·çʪ¹Ø½ÚÑ×·¢Õ¹±¨¸æ2020¡·ÏÔʾ£¬RA»¼Õß´Ó³öÏÖÖ¢×´µ½Ã÷È·Õï¶Ïƽ¾ùʱ¼äÔÚ2ÄêÒÔÉÏ£¬ÆäÖÐÔ¼40%µÄ»¼Õß´¦Óڸ߼²²¡»î¶¯×´Ì¬£¬´í¹ýÁË6¸öÔÂÖÁ1ÄêµÄ×î¼ÑÖÎÁÆÊ±¼ä´°¡£Òò´Ë£¬¾«×¼Ê¶±ðÀà·çʪ¹Ø½ÚÑ×ÁÙ´²Ç°ÆÚ£¨Pre-RA£©£¬×¥×¡¡°»ú»á´°¿Ú¡±ÓÈÎªÖØÒª¡£

ÎÒ¹úRA»¼²¡ÂÊΪ0.42%£¬»¼Õß×ÜÊýÔ¼500ÍòÈË£¬ÇÒ³ÊÏÖ¶àÕïÖÎÑÓÎ󡢶ಡÇéÖØºÍ¶àºÏ²¢Ö¢µÄÌØµã£¬Ëæ×ÅRAÏà¹ØÑо¿µÄ½øÕ¹£¬RAµÄÔ¤·ÀÔ½À´Ô½Êܵ½ÖØÊÓ£¬ÆÕ±éÈÏΪͨ¹ýÔçÆÚÔ¤·À¿É¸ÄÉÆRA»¼ÕßµÄÔ¤ºó¡£


ÈçºÎ¶¨Òå¡°RAǰ״̬¡±

2012ÄêÅ·ÖÞ¿¹·çʪ²¡ÁªÃË£¨EULAR£©RA·çÏÕÒòËØÑо¿Ð¡×éÌá³öÁË¡°ÁÙ´²Ç°ÆÚRA£¨pre-RA£©¡±µÄ¸ÅÄ¼´¡°RAǰ״̬¡±¡£¸ÃÊõÓï±»ÍÆ¼ö½öÓÃÓڻعËÐÔÃèÊöRA»¼ÕßRAÕï¶Ï֮ǰµÄÏà¹Ø½×¶Î£»¸ÃС×齫RAµÄ·¢Éú·¢Õ¹¹ý³Ì·ÖΪ6¸ö½×¶Î£ºRAÏà¹ØÒÅ´«·çÏÕÒòËØ½×¶Î¡¢RAÏà¹Ø»·¾³ÒòËØ½×¶Î¡¢RAÏà¹ØÏµÍ³ÐÔ×ÔÉíÃâÒ߽׶Ρ¢ÎÞÁÙ´²¹Ø½ÚÑ×Ö¢×´½×¶Î¡¢Î´·Ö»¯¹Ø½ÚÑ׽׶μ°·ÖÀàÕï¶ÏRA½×¶Î£»pre-RA°üÀ¨³ý·ÖÀàÕï¶ÏRA½×¶ÎÒÔÍâµÄ5¸ö½×¶Î¡£

Ò»Ö±ÒÔÀ´£¬RAÒò¾ßÓв¡³ÌÂþ³¤¡¢Ö²ÐÂʸߵÈÌØµã£¬±»³ÆÎª¡°²»ËÀµÄ°©Ö¢¡±£¬ÑÏÖØÓ°Ï컼ÕßµÄÉíÐĽ¡¿µºÍÉú»îÖÊÁ¿¡£Ëæ×ÅÈËÃǶÔRAÈÏʶµÄ²»¶Ï¼ÓÉ´óÁ¿µÄÎÄÏ×Ö¸ÄÏÖ¸³ö£ºRAÔçÆÚÕï¶Ï¶ÔÖÎÁƺÍÔ¤ºóÓ°ÏìÖØ´ó¡£

1.png

 

Ϊ½øÒ»²½Ö¸µ¼ºÍ¼ÓÇ¿RAµÄÔçÆÚÔ¤·ÀºÍÕï¶Ï£¬2024Äê·¢²¼µÄ¡¶Àà·çʪ¹Ø½ÚÑ×ǰ״̬ÕïÁÆ×¨¼Ò¹²Ê¶¡·(ÒÔϼò³Æ¡°¹²Ê¶¡±)¾ÍÀà·çʪ¹Ø½ÚÑ×ǰ״̬µÄɸ²é¡¢Õï¶Ï¡¢ÖÎÁƵȸøÓëÍÆ¼öÒâ¼û¡£   

2.png


Õï¶Ï¡°RAǰ״̬¡±µÄÌØÒìÐÔ·Ö×Ó±êÖ¾ÎïÓÐÄÄЩ£¿

¹²Ê¶ÍƼö¡°RAǰ״̬¡±»¼ÕßÁªºÏ¼ì²â¿¹CCP¿¹Ìå¡¢¿¹½Çµ°°×¿¹Ìå(AKA)¡¢Àà·çʪÒò×Ó(RF)ºÍ¿¹ºËÖÜÒò×Ó(APF)£¬ÆÀ¹Àת»¯ÎªRAµÄ·çÏÕ¡£¿¹CCP¿¹ÌåÔÚÔ¤²â¡°RAǰ״̬¡±½øÕ¹ÎªRAµÄ¹ý³ÌÖÐÖÁ¹ØÖØÒª£¬Òò´Ë½«¿¹CCP¿¹Ìå¼ì²âÁÐÈë¡°RAǰ״̬¡±µÄÕï¶Ï¹ý³Ì¡£

2010Ä꣬һÏîǰհÐÔ¶ÓÁÐÑо¿[2](147Àý)ÏÔʾ,ÓзÇÌØÒìÐÔ¼¡Èâ¹Ç÷À(MSK)Ö¢×´ÇÒ¿¹CCP¿¹ÌåÑôÐÔ»¼Õߣ¨100Àý£©£¬¾­¹ý19.8¸öÔ£¨ÖÐλÊý£©Ëæ·Ãºó£¬86%(43/50)»¼ÕßÂú×ã2010ÄêACR/EULAR¶ÔRAµÄÕï¶Ï±ê×¼¡£2018Äê,Ò»ÏîϵͳÆÀ¼Û[3]ÏÔʾ¿¹CCP¿¹ÌåÓëRFË«ÑôÐÔ¶ÔRAǰ״̬½øÕ¹ÎªRAµÄÔ¤²âÌØÒìÐÔΪ97.6%~100.0%,Ãô¸ÐÐÔΪ21.5%~35.5%£¬AUC 0.608~0.665ÑôÐÔËÆÈ»±È14.6~44.3,ÒõÐÔËÆÈ»±È0.7~0.8.OR=36£¬95%CI¡£


 ¡°RAǰ״̬¡±ÈçºÎÕï¶Ï£¿

 

3.png

4.png 

 

Õï¶Ï²½Ö裨ͼ1£©£ºRAǰ״̬ÒÉËÆÕßÏÈͨ¹ý±í2½øÐÐÕï¶Ï¡£±í2ÊÇ2017ÄêEULAR¶ÔÒÉËÆ½øÕ¹ÎªRAµÄ¹Ø½ÚÍ´µÄÕï¶Ï±ê×¼£¬·ûºÏ¸Ã±ê×¼ÏîÄ¿Êý¡Ý5ÌõÊ±ÌØÒì¶ÈΪ100%£¬¼´ÈôÕï¶Ï¶ÔÏó·ûºÏÏîÄ¿Êý¡Ý5ÌõÔò¿ÉÕï¶ÏΪRAǰ״̬£»Èô·ûºÏ±í2ÌõÄ¿Êý£¼5Ìõ£¬ÇÒ¿¹CCP¿¹ÌåÑôÐÔÕßʹÓñí3½øÐÐÕï¶Ï¡£±í3ÊÇÐÞ¶©ºóµÄ2010 ACR/EULARµÄRAÕï¶Ï±ê×¼¡£µ±Õï¶Ï¶ÔÏó¼ÈÂú×ã±í3ÖеÄÏîÄ¿1£¬ÓÖÂú×ãÏîÄ¿2×ÜÆÀ·Ö¡Ü5·Öʱ£¬Ôò¿ÉÕï¶ÏΪRAǰ״̬¡£·ñÔò£¬Õï¶Ï¶ÔÏóÅųýRAǰ״̬¡£

RAËäȻĿǰûÓг¹µ×ÖÎÓúµÄ·½·¨£¬µ«Í¨¹ýÔçÆÚµÄɸ²éºÍÕï¶Ï£¬¿ÉÒÔÓÐЧ·¢ÏÖÀà·çʪ¹Ø½ÚÑ×ǰ״̬ÈËȺ£¬¸üÔç¸üÓÐЧµØ¿ØÖƼ²²¡½øÕ¹£¬Ìá¸ß»¼ÕßµÄÉú»îÖÊÁ¿¡£


ÔÆ¶¥¼¯Íżò½éÕë¶ÔÀà·çʪ¹Ø½ÚÑ׵ļì²â·½°¸ 

ÔÆ¶¥¼¯Íżò½é¾ß±¸RF¡¢ASO¡¢¿¹CCPÒÔ¼°CRPµÈ·çʪÃâÒßÀàÏîÄ¿µÄ¼ì²âÊÔ¼Á£¬Ñ¡ÓÃÓÅÖʸßÌØÒìÐÔ¿¹Ì壬ÁéÃô¶È¸ß£¬ÏßÐÔ·¶Î§¿í£¬¿ÉΪÀà·çʪÐÔ¼²²¡Ìṩ׼ȷ¡¢È«ÃæµÄÕï¶ÏÒÀ¾Ý¡£Ôƶ¥¼¯Íżò½éÅäÌ×µÄÈ«×Ô¶¯Ìض¨µ°°×·ÖÎöÒDzÉÓþ­µäµÄÃâÒßÉ¢Éä±È×Ç·¨£¬×Ô¶¯»¯³Ì¶È¸ß£¬²Ù×÷¼ò±ã£¬Å䱸¿¹Ô­¹ýÊ£×Ô¶¯Öز⹦ÄÜ£¬ÇáËÉÓ¦¶Ô¸ßÖµÑù±¾¼ì²â¡£Õë¶Ô´óÑù±¾Á¿¼ì²âÐèÇ󣬿ɸù¾Ý¿ÆÊÒÐèÇó½øÐÐÄ£¿é»¯×éºÏÐγÉÈ«×Ô¶¯Ìض¨µ°°×·ÖÎöÁ÷Ë®Ïߣ¬¶ą̀¼¶Áª¿ÉʵÏÖ×î¿ì800T/H²âËÙ£¬Äܹ»´ó´óÌáÉý¼ì²âЧÂÊ£¬ÓÅ»¯¼ì²âÁ÷³Ì¡£   

 5.png

 

640.png

²Î¿¼ÎÄÏ×£º

[1]¡¶Àà·çʪ¹Ø½ÚÑ×ǰ״̬ÕïÁÆ×¨¼Ò¹²Ê¶¡·ÖлªÖÐÒ½Ò©ÔÓÖ¾(Ô­Öйúҽҩѧ±¨)2024Äê2ÔµÚ39¾íµÚ2ÆÚ CJTCMP, February 2024, Vol.39, No.2

[2] BOS W H,WOL.BINK G J,BOERS M.et al.Arhritis development inpatients with arthralgia is strongly assoeiated with anti-citrullinatedprotein antibody status:A prospective cohort study.Ann RheumDis,2010,69(3):490-494

[3] VERHEUL M K,BOHRINGER S,VAN DELFT M.et al.Triplepositivity for anti-citrullinated protein autoantibodies,rheumatoidfactor,and anti-carbamylated protein antibodies conferring highspecificity for rheumatoid arthritis:lmplieations for very earlyidentification of at-risk individuals.Arthritis Rheumatol,2018.70(11):1721-1731